The Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, are joined by Rachna Shroff, MD, to discuss recent data updates in gastrointestinal cancers from clinical trials presented at the 2023 ESMO Congress Meeting.
EP. 1: Codebreak300: Sotorasib Plus Panitumumab in KRAS G12C-Mutated Metastatic Colorectal Cancer
Rachna Shroff, MD, chief of the Division of Hematology and Oncology in the Department of Medicine at the University of Arizona College of Medicine, highlights key data from the Codebreak300 study evaluating if the combination of sotorasib and panitumumab is superior to standard-of-care trifluridine/tipiracil or regorafenib in the setting of chemorefractory metastatic colorectal cancer.
EP. 2: CABINET: Cabozantinib Versus Placebo in Patients With Advanced Neuroendocrine Tumors After Progression on Everolimus
Expert medical oncologists review data from the CABINET trial evaluating cabozantinib compared with placebo in two cohorts of previously treated patients with neuroendocrine tumors.
EP. 3: GASTFOX: Evaluate FOLFOX With or Without Docetaxel (TFOX) as First-Line Chemotherapy for Locally Advanced or Metastatic Esophago-Gastric Carcinoma
Rachna Shroff, MD, details key data from the phase III GASTFOX study comparing FOLFOX to docetaxel (TFOX) in the first line treatment of advanced gastric cancer.
EP. 4: Closing Thoughts on Recent Data in GI Cancers From ESMO 2023
Rohit Gosain, MD, and Rahul Gosain, MD, provide a summary of the key gastrointestinal cancer data updates discussed following the 2023 ESMO Congress Meeting.
2 Clarke Drive Cranbury, NJ 08512